EGFR and lung carcinoma: Testing for plasma epidermal growth factor receptor (EGFR) mutations has FDA clearance for selection of mutant lung cancer patients for EGFR tyrosine kinase inhibitors and studies of plasma DNA in multiple indications have suggested clinical utility for monitoring of mutations or copy number (CN) gain [3–6].